Fused triazole derivatives as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes
View Patent ↗The present invention is directed to novel fused triazole derivatives which are inhibitors of the dipeptidyl peptidase-IV enzyme (“DPP-IV inhibitors”) and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly type 2 diabetes. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the dipeptidyl peptidase-IV enzyme is involved.
1. A compound of the formula I:
or a pharmaceutically acceptable salt thereof; wherein
“a” and “b” represent single or double bonds;
Ar is phenyl, which is unsubstituted or substituted with one to five R 3 substituents;
each R 3 is independently selected from the group consisting of:
(1) halogen,
(2) C 1-6 alkyl, which is unsubstituted or substituted with one to five halogens,
(3) C 1-6 alkoxy, which is unsubstituted or substituted with one to five halogens,
(4) CN, and
(5) hydroxyl;
A is CH 2 , O, S, or a single bond;
D-E together are —CH 2 CH 2 — or —CH═CH—,when A is a single bond; or —CH 2 CH 2 — when A is CH 2 , O, or S;
L-M together represents a fused ring selected from the group consisting of:
R 1 and R 2 are each independently selected from the group consisting of:
(1) hydrogen,
(2) C 1-10 alkyl, which is unsubstituted or substituted with:
(a) one to five halogens or
(b) phenyl, which is unsubstituted or substituted with one to five substituents independently selected from halogen, CN, OH, R 4 , OR 4 , NHSO 2 R 4 ,
N(C 1-6 alkyl)SO 2 R 4 , SO 2 R 4 , SO 2 NR 5 R 6 , NR 5 R 6 , CONR 5 R 6 , CO 2 H, and CO 2 C 1-6 alkyl,
(3) phenyl which is unsubstituted or substituted with one to five substituents independently selected from halogen, CN, OH, R 4 , OR 4 , NHSO 2 R 4 , N(C 1-6 alkyl)SO 2 R 4 , SO 2 R 4 , SO 2 NR 5 R 6 , NR 5 R 6 , CONR 5 R 6 , CO 2 H, and CO 2 C 1-6 alkyl,
(4) a 5- or 6-membered heterocycle which may be saturated or unsaturated containing one to four heteroatoms independently selected from N, S and O, said heterocycle being unsubstituted or substituted with one to three substituents independently selected from oxo, halogen, NO 2 , CN, OH, R 4 , OR 4 , NHSO 2 R 4 , N(C 1-6 alkyl)SO 2 R 4 , SO 2 R 4 , SO 2 NR 5 R 6 , NR 5 R 6 , CONR 5 R 6 , CO 2 H, and CO 2 C 1-6 alkyl,
(5) C 3-6 cycloalkyl, which is unsubstituted or substituted with one to three substituents independently selected from halogen, OH, C 1-6 alkyl, and C 1-6 alkoxy, wherein alkyl and alkoxy are optionally substituted with one to five halogens,
(6) OH,
(7) OR 4 ,
(8) SR 4 ,
(9) SO 2 R 4 ,
(10) SO 2 NR 5 R 6 ,
(11) NR 5 R 6 ,
(12) CN,
(13) CO 2 H,
(14) CO 2 C 1-6 alkyl,
(15) CONR 5 R 6 , and
(16) halogen;
R 4 is C 1-6 alkyl, which is unsubstituted or substituted with one to five substituents independently selected from halogen, CO 2 H, and CO 2 C 1-6 alkyl;
R 5 and R 6 are each independently selected from the group consisting of:
(1) hydrogen,
(2) phenyl, which is unsubstituted or substituted with one to five substituents independently selected from halogen, OH, C 1-6 alkyl, and C 1-6 alkoxy, wherein alkyl and alkoxy are optionally substituted with one to five halogens,
(3) C 3-6 cycloalkyl, which is unsubstituted or substituted with one to three substituents independently selected from halogen, OH, C 1-6 alkyl, and C 1-6 alkoxy, wherein alkyl and alkoxy are optionally substituted with one to five halogens, and
(4) C 1-6 alkyl, which is unsubstituted or substituted with a substituent selected from the group consisting of:
(a) one to five halogens,
(b) OH,
(c) C 1-6 alkoxy, and
(d) phenyl, which is unsubstituted or substituted with one to five substituents independently selected from halogen, OH, C 1-6 alkyl, and C 1-6 alkoxy, wherein
alkyl and alkoxy are optionally substituted with one to five halogens;
or R 5 and R 6 together with the nitrogen atom to which they are attached form a heterocyclic ring selected from azetidine, pyrrolidine, piperidine, piperazine, and morpholine wherein said heterocyclic ring is unsubstituted or substituted with one to five substituents independently selected from halogen, hydroxy, C 1-6 alkyl, and C 1-6 alkoxy, wherein alkyl and alkoxy are unsubstituted or substituted with one to five halogens; and
R 7 is hydrogen or C 1-4 alkyl.
2. The compound of claim 1 wherein the carbon atom marked with an * has the R stereochemical configuration as depicted in structural formula Ia:
3. The compound of claim 2 of the structural formula Ib:
4. The compound of claim 3 of the structural formula Ib2:
5. The compound of claim 2 of the structural formula Ie:
6. The compound of claim 5 of the structural formula Ie3:
7. The compound of claim 5 of the structural formula Ie6:
8. The compound of claim 2 of the structural formula If:
9. The compound of claim 8 of the structural formula If1:
10. The compound of claim 8 of the structural formula If2:
11. The compound of claim 8 of the structural formula If4:
12. The compound of claim 8 of the structural formula If5:
13. The compound of claim 8 of the structural formula If6:
14. The compound of claim 8 of the structural formula If7:
15. The compound of claim 1 wherein L-M together represents a fused ring selected from the group consisting of:
16. The compound of claim 1 wherein Ar is selected from the group consisting of phenyl; 2-fluorophenyl; 3,4-difluorophenyl; 2,5-difluorophenyl; and 2,4,5-trifluorophenyl.
17. The compound of claim 1 wherein R 1 and R 2 are each independently selected from the group consisting of:
(1) hydrogen,
(2) methyl,
(3) CF 3 ,
(4) phenyl which is unsubstituted or substituted with one to three fluorines,
(5) C 02 C 1-4 alkyl,
(6) CONR 5 R 6 ,
(7) fluorine, and
(8) chlorine.
18. The compound of claim 1 wherein R 5 and R 6 are each independently selected from the group consisting of:
(1) hydrogen,
(2) cyclopropyl, and
(3) C 1-4 alkyl, which is linear or branched and which is unsubstituted or substituted with fluoro, OH, C 1-4 alkoxy;
or wherein R 5 and R 6 together with the nitrogen atom to which they are attached form a heterocyclic ring selected from azetidine, pyrrolidine, piperidine, piperazine, and morpholine wherein said heterocyclic ring is unsubstituted or substituted with one or two substituents independently selected from fluoro, hydroxy, Me, and OMe.
19. The compound of claim 1 which is selected from the group consisting of:
or a pharmaceutically acceptable salt thereof.
20. A pharmaceutical composition which comprises a compound of claim 1 and a pharmaceutically acceptable carrier.
21. The pharmaceutical composition of claim 20 additionally comprising metformin.
22. A method for treating non-insulin dependent (Type 2) diabetes in a mammal in need thereof which comprises the administration to the mammal of a therapeutically effective amount of a compound of claim 1 .